Published online Dec 28, 2017. doi: 10.4254/wjh.v9.i36.1346
Peer-review started: September 22, 2017
First decision: November 3, 2017
Revised: November 14, 2017
Accepted: December 4, 2017
Article in press: December 5, 2017
Published online: December 28, 2017
Processing time: 107 Days and 12.2 Hours
Gender disparities have been noted in the treatment of hepatocellular carcinoma (HCC), specifically with liver transplantation.
There has been an emphasis on evaluating gender disparities in healthcare; HCC is not an exception. Gender disparities in the treatment for HCC have been noted in the past, specifically in transplantation. Studies reveal that men were more likely to receive a liver transplantation during pre-model for end stage liver disease (MELD) organ allotment, while women were more likely to die while waiting for organ transplantation. Other studies have concluded that women were more likely to receive resection for earlier stage disease.
The aim of this study is to determine if disparities continue to exist despite an emphasis to reduce disparities in healthcare.
A retrospective database analysis utilizing the NIS was performed.
The authors determined that women are more likely to undergo an ablation or resection then men. Disparities in liver transplantation have resolved. Further research should be completed to determine ways to reduce gender disparities in hepatocellular carcinoma given the effect this has on patient mortality and healthcare cost.
This study shows that a gender difference in the treatment of HCC continues to exist, specifically with resection and ablation. It is important to recognize this disparity and make an effort to reduce this given that interventions are associated with decreased financial burden and lower 30-d mortality rate.
It is unclear why the previous disparity continues to exist, and further research should be completed to determine the cause and ways to reduce this difference between genders.